FDA Approves Reintroduction of OTC Primatene Mist 
On November 7, 2018, FDA’s CDER approved a new version of Primatene Mist as the only OTC metered-dose inhaler. Primatene is for the temporary relief…
John EvansJanuary 28, 2019
Latest News
PEGUS Presentation on OTC Consumer Research at 2018 CHPA RSQ Conference
Key staff from PEGUS (Dr. Russ Bradford, Sarah Farnsworth, Kimberly Anderson and Clark Richardson) participated in an innovative session at the 2018 Regulatory, Scientific and…
John EvansJune 27, 2018
Clark Richardson Presents at April 2018 CHPA Consumer Behavior Roundtable
On April 17, members of the PEGUS scientific consulting team participated in the CHPA Consumer Behavior Roundtable in Silver Spring, Maryland. The roundtable was attended…
John EvansJune 27, 2018
Study Conducted by PEGUS Research Published in JAPhA
A Self-Selection and Actual Use Trial conducted by PEGUS Research that investigated whether consumers can correctly select and use a long-acting immediate-release and extended-release 600…
John EvansJune 27, 2018
PEGUS Research Results Published in International Journal of Clinical Pharmacology and Therapeutics 
Results from a US actual use trial conducted by PEGUS to evaluate consumer adherence to dosing directions for a 400 mg OTC pain reliever were…
Chad MarquezMay 11, 2018
